Results No significant differences in periventricular venous density indicated by PVA were detectable in NMOSD versus healthy controls (p = 0.226). In contrast, PVA was significantly reduced in MS patients compared to healthy controls (p = 0.013). Conclusion Unlike patients with MS, those suffering from NMOSD did not show reduced venous visibility. This finding may underscore primary and secondary pathophysiological differences between these two distinct diseases of the central nervous system.
nervous system conditions predominantly affecting the spinal cord and optic nerve [1] [2] [3] [4] . Prior to the discovery of a serum immunoglobulin G antibody targeting the aquaporin-4 water channel [5, 6] , the disorder was often considered a variant of multiple sclerosis (MS), as the clinical presentation of these two distinct central nervous system (CNS) diseases may overlap [1] . Indeed, patients with NMOSD are still often misdiagnosed with MS in clinical practice [7, 8] .
Magnetic resonance imaging (MRI) has improved our pathophysiological understanding of various CNS diseases. Driven by improvements in gradient-echo MRI techniques [9] , intracranial veins can now be studied in vivo at 1.5T and 3T, e.g., applying three-dimensional (3D) susceptibility-weighted imaging (SWI).
With gains from increased signal-to-noise ratio and susceptibility effects, and hence increased sensitivity to venous deoxyhemoglobin concentration, ultrahigh-field MRI at 7T has advanced the visualization of even small intracranial veins [10, 11] , improving the characterization of brain lesions and facilitating the differentiation between MS and NMOSD [12, 13] . In MS, reduced visibility of the cerebral venous system was recently reported [14, 15] , but the reason for diminished visibility of the venous vasculature on 7T T 2 *w images in MS remains to be clarified. It may result from reduced oxygen consumption as a consequence of a widespread cerebral gliosis and hypometabolic state, leading to reduced deoxygenation of the brain's venous blood and thus less susceptibility-related signal loss on T 2 *w images [14, 15] .
It is not known whether venous density is altered in NMOSD. In this work, we aimed to quantify periventricular venous density in NMOSD, including a careful comparison between healthy control subjects and patients with NMOSD and MS.
Materials and methods

Study participants
A synopsis of the demographic and clinical details of participants is presented in Table 1 . Sixteen NMOSD patients underwent ultrahigh-field MRI at 7T. All NMOSD patients were seropositive for aquaporin-4-IgG. Inclusion criteria were diagnosis of NMOSD as defined by current international consensus diagnostic criteria [1] , age of at least 18 years, and no contraindications to 7T MRI. Sixteen patients with relapsing-remitting MS as defined by the current panel criteria [16] , and 16 agematched healthy control subjects most comparable to the NMOSD cohort in terms of gender, age and-if applicable-disease duration were selected from a research database of the NeuroCure Clinical Research Center (NCRC). Neurological disability was assessed with the Kurtzke Expanded Disability Status Scale (EDSS) [17] . The study was approved by the local ethics committee. Written informed consent was obtained from all subjects prior to the study.
MRI data acquisition
Ultrahigh-field magnetic resonance images were acquired using a 7T whole-body MRI system (Magnetom; Siemens, Erlangen, Germany) and a 24-channel RF head coil (Nova Medical, Wilmington, MA, USA).
The imaging protocol included:
• Two-dimensional axial T 2 *w fast low-angle shot acquisitions (FLASH; TE = 25.0 ms; TR = 1820 ms; flip 
Image analysis
Images were analysed using the OsiriX software package (version 3.8.1; Osirix Foundation, Genève, Switzerland) by an investigator (SS) blinded to clinical data (diagnosis, disease duration, EDSS). We decided to use a manual approach for estimating the periventricular venous density, since signal inhomogeneities on 7T T 2 *w images affect automated segmentation procedures. The periventricular vascular area (PVA) was assessed as described previously ( Fig. 1 ) [14] . In brief, first, a minimum-intensity projection (MIP) map of the two adjacent axial T 2 *w slices tangential to the roof of the lateral ventricles was calculated. This procedure eliminates the risk of double-counting venous voxels in two neighbouring slices, and improves the visibility of venous structures. Next, a squared region of interest (ROI) with a length of 4 cm and a width of 1 cm was defined for both brain hemispheres and positioned between the frontal and occipital horns. The investigator then manually marked each venous voxel with a signal intensity of less than 10 % of the mean signal intensity of the neighbouring normal-appearing vein-free white matter. The applied 10 % threshold builds on previous reports [14] . To determine the mean signal intensity of the neighbouring normal-appearing vein-free white matter, multiple ellipsoid ROIs with an area of 2 mm 2 were used as a reference. Finally, the PVA (in mm 2 ) was calculated as the sum of all venous voxels.
The left hemisphere of one MS patient was excluded from analysis due to previous brain biopsy in this area. Lesion count was conducted in a separate analysis of the FLAIR images. A lesion was defined as a hyperintensity relative to the surrounding normal-appearing white or grey matter with a diameter of at least 3 mm.
Statistical analysis
All analyses were performed using IBM SPSS Statistics software (version 22; IBM Corp., Armonk, NY, USA). P values <0.05 were considered significant. Group differences in gender were analysed using a chi-square test. Group differences in PVA and age between patients with MS and NMOSD and healthy control subjects were assessed using a parametric Student t test. Normality of PVA and age was assessed previously using visual analysis and the Shapiro-Wilk test (PVA, p = 0.931; age, p = 0.188). Group differences in lesion count, time since first symptoms, and EDSS were assessed using a non-parametric Mann-Whitney U test, since these variables were not normally distributed (Shapiro-Wilk; lesion count, p < 0.001; time since first symptoms, p < 0.001; EDSS, p = 0.043). Thus, associations between lesion count and PVA were assessed using non-parametric Spearman correlation. Statistical dependencies between age and PVA were assessed using parametric Pearson correlation. Finally, gender differences in PVA were analysed by using a Mann-Whitney U test.
Results
In total, we detected 118 (mean ± SD, range; 7 ± 10, 0-38) cerebral FLAIR hyperintense white matter lesions in 12 of 16 NMOSD patients and 355 (mean ± SD, range; 22 ± 19, 0-65) cerebral white matter lesions in 15 of 16 MS patients. A total of 112 (mean ± SD, range; 7 ± 13, 0-42) white matter lesions were seen in 9 of 16 healthy control subjects. These lesions in healthy controls were non-specific in Fig. 1 Method of analysis. A minimum-intensity projection map of two T 2 *w image slices of an exemplary healthy control is presented. The blinded investigator masked each venous voxel (red area) in two squared regions of interest (ROIs, green box), as described in the methods section appearance and potentially related to small vessel disease in a subgroup of older healthy control subjects.
Visual inspection of 7T T 2 *w images showed the periventricular venous system to be altered in MS patients compared to healthy controls. In contrast, no obvious differences were apparent when NMOSD patients were compared to healthy control subjects. To highlight these findings, Fig. 2 shows T 2 *w images deduced from exemplary MS and NMOSD patients.
Periventricular vascular area in healthy control subjects and NMOSD and MS patients
In healthy control subjects, mean PVA was 144 mm 2 (SD 27 mm 2 , range 92-202 mm 2 ). PVA was not associated with gender in healthy control subjects (p = 0.713), which is in agreement with previous published results [14] . However, we observed a trend towards smaller PVA values in older healthy control subjects (r = −0.458, p = 0.074).
When comparing NMOSD patients with healthy control subjects, we did not observe any differences in PVA (NMOSD, mean ± SD, range; 133 ± 21, 98-170 mm 2 , p = 0.226), as outlined in Fig. 3 . In contrast, PVA was significantly reduced in patients with MS (mean ± SD, range; 117 ± 30, 61-173 mm 2 ) compared to healthy control subjects (p = 0.013, Fig. 3 ). There was a trend towards smaller PVA in MS versus NMOSD (p = 0.090).
Associations with lesion count
Finally, we asked whether these differences in periventricular venous density could be due to group differences in lesion count, since the periventricular venous visibility was reported to be inversely correlated with the number of T 2 w lesions in MS patients [14] . Indeed, we observed an inverse correlation between the lesion count and PVA in our MS group (r s = −0.555, p = 0.026). No such association was seen in patients with NMOSD (r s = 0.120, p = 0.658).
Discussion
Increased spatial resolution and susceptibility effects of ultrahigh-field MRI at 7T allow for markedly improved visualization of the brain's venous system. We have taken advantage of these capabilities to analyze the periventricular venous system in patients with NMOSD in comparison to those with MS and healthy volunteers. While the periventricular venous visibility was diminished in MS compared to both NMOSD and healthy controls, there was no To interpret our findings, one must consider the cause of the superb visibility of venous structures in 7T T 2 *w or susceptibility-weighted images: deoxygenated haemoglobin is a compound with paramagnetic properties, leading to susceptibility-related signal loss in gradient-echo MR images. In contrast, oxygenated haemoglobin is diamagnetic. Thus, the venous visibility is highly dependent on the degree of (de-)oxygenation. Other factors, such as the velocity of the venous blood flow or the size of the venous vessel, could also impact the visibility of veins on T 2 *w images.
Various studies in MS patients have recently identified changes in the visibility of small veins on T 2 *w images [14, 15] . The diminished visibility of the veins in MS may be due to a widespread cerebral hypometabolic state as a result of neurodegeneration. This leads to reduced deoxygenation of the brain's venous blood and, consequently, less susceptibility-related signal loss on T 2 *w images [14, 15] . This hypothesis is further supported by a quantitative MRI study that reported significantly increased venous oxygenation levels and decreased cerebral metabolic rates of oxygen in MS patients compared with healthy controls [18] . Furthermore, vascular damage, a sequel to (perivascular) inflammation and gliosis [19] in MS, is associated with globally reduced cerebral perfusion [20] , and may thus contribute to diminished venous visibility on T 2 *w images [14, 15] . Another possible cause of decreased oxygen uptake is the high level of nitric oxide (NO) due to repetitive vascular inflammation in MS competitively inhibiting mitochondrial uptake of oxygen [18] .
In contradistinction to MS, venous density in NMOSD patients was found to be similar to that in healthy controls.
The comprehensive interpretation of this finding remains controversial. One valuable hypothesis is that brain damage and neurodegeneration in NMOSD is less severe and more focal in nature than that in MS. Therefore, cerebral hypometabolism seen in MS may not be a feature of NMOSD, or may be present to a much lesser extent. This could explain normal measures of venous density in NMOSD.
Whether, and to what extent, diffuse brain damage occurs in NMOSD is a matter of controversy [21] [22] [23] [24] [25] . On the one hand, studies using volumetrics [23] , spectroscopy [22] , and diffusion tensor imaging (DTI) [24] have shown that diffuse brain atrophy in NMOSD is less pronounced than in MS, or even similar to healthy control subjects. Other studies have identified widespread brain alterations in NMOSD [21, 26] . These changes, however, were less severe than in MS, which is in line with our results showing a weak trend of smaller PVA values in NMOSD versus healthy volunteers.
In our study, venous density in NMOSD-in contrast to that in MS-was not associated with the number of brain lesions. This discrepancy might be a consequence of more diffuse structural damage such as brain parenchymal gliosis in MS versus NMOSD, causing decreased PVA in MS.
A limitation of this study, in which periventricular venous density was assessed using a manual approach, is the small sample size of the cohort and respective low power in detecting subtle vascular changes. Although all images were anonymized, blinding to the MS diagnosis was not always achievable as a consequence of the existence of lesions strongly suggestive of MS. Minor motion artefacts may have also biased our results. Despite the absence of any gender differences in PVA in healthy control subjects, we cannot exclude the influence of gender differences between NMOSD and healthy control subjects on our results.
Conclusion
In conclusion, the periventricular venous system appeared similar in NMOSD and healthy controls on 7T T 2 *w images. This finding is in contrast to that in MS, and may highlight pathogenetic differences between these distinct autoimmune neuroinflammatory disease entities. Fig. 3 No statistically significant differences in periventricular venous density indicated by PVA were detectable between patients with NMOSD and healthy volunteers
